HotSpot Therapeutics, Inc. v. Nurix Therapeutics, Inc.

District Court, N.D. California·Decided May 3, 2023·No. 3:22-cv-04109·Unknown

Opinion

1 2 3 6 7 HOTSPOT THERAPEUTICS, INC., Case No. 22-cv-04109-TSH

8 Plaintiff, ORDER RE: PLAINTIFF/COUNTERCLAIM 9 v. DEFENDANT’S MOTION TO STAY DISCOVERY (PUBLIC REDACTED 10 NURIX THERAPEUTICS, INC., VERSION OF ECF NO. 101) 11 Defendant. Re: Dkt. Nos. 72, 73, 80, 88, 89, 90, 96

12 14 Pending before the Court are Plaintiff/Counterclaim Defendant HotSpot Therapeutics, 15 Inc.’s (“HotSpot’s”) Motion to stay discovery until Nurix Therapeutics, Inc. (“Nurix”) satisfies the 16 pre-discovery requirement to identify the trade secrets it alleges to be misappropriated by HotSpot 17 (ECF No. 73) and related Administrative Motions to Seal (ECF Nos. 72, 80, 90). On March 16, 18 2023, Nurix filed Opposition. ECF No. 81. On March 23, 2023, HotSpot filed a Reply. ECF No. 19 91. Additionally pending is a Motion to strike portions of Nurix’s Opposition (ECF No. 89) and 20 related Administrative Motions to Seal (ECF Nos. 88, 96). On April 6, 2023, Nurix filed 21 Opposition to the Motion to strike (ECF No. 97) and on April 13, 2023, HotSpot filed a Reply 22 (ECF No. 100). 23 Having considered the parties’ positions, relevant legal authority, and the record in this 24 case, the Court issues the following order GRANTING IN PART AND DENYING IN PART 25 the parties’ administrative motions to seal, DENYING HotSpot’s Motion to Strike, and 26 GRANTING IN PART AND DENYING IN PART HotSpot’s Motion to Stay Discovery. 1 DNA-encoded libraries (DELs), and a “DELigase platform” to target proteins to treat cancer and 2 diseases. ECF No. 50 (Counterclaims) ¶ 9. DEL technology can be used to accelerate the process 3 of discovering new drugs, and DELs are large collections of small molecules that are screened 4 against targets to identify drug-like molecules. Id. ¶ 12. 5 In September 2015, Nurix and Macroceutics, Inc. (“Macroceutics”) entered into a 6 collaborative agreement (“the Agreement”). ECF No. 73 at 9; ECF No. 81 at 6. Nurix alleges that 7 during the collaboration Nurix shared its confidential and trade secret information with 8 Macroceutics. ECF No. 81 at 6. According to Nurix’s counterclaims, these trade secrets involved 9 chemistry designs, aqueous chemical synthesis, combinatorial chemistry, purification methods, 10 quality control methods, encoding designs, and Nurix’s DNATag software. ECF No. 50 ¶ 20. 11 In August 2019, HotSpot acquired Macroceutics. Id. ¶ 31. The Agreement applies to 12 HotSpot as successor in interest to Macroceutics. Id. ¶ 32. Nurix alleges HotSpot used Nurix’s 13 confidential and proprietary information, without notice to or permission of Nurix, to design or 14 build DELs. Id. ¶ 50. 15 On July 13, 2022, HotSpot filed the instant action, seeking declaratory judgment of 1) no 16 misappropriation under the Defend Trade Secrets Act (“DTSA”); 2) no misappropriation under the 17 California Uniform Trade Secrets Act (“CUTSA”); and 3) no breach of contract. Id. ¶¶ 64-85. On 18 November 23, 2022, Nurix filed an Amended Answer to Complaint and Counterclaims (“First 19 Amended Answer”). ECF No. 50. On December 7, 2022 HotSpot filed a Motion to Dismiss 20 Nurix’s Amended Counterclaims, and on February 3, 2023, the Court issued an Order granting in 21 part and denying in part dismissal. ECF Nos. 57, 65. As a result of the February 3, 2023 Order, 22 Nurix’s remaining Counterclaims are as follows: 1) Misappropriation of Trade Secrets under the 23 DTSA; 2) Misappropriation of Trade Secrets under the CUTSA; 3) Breach of Contract; and 4) 24 Intentional Interference with Performance of a Contract (“IIPC”). ECF Nos. 50, 65. 25 On December 30, 2022, Nurix served its “Identification of Asserted Trade Secrets 26 Pursuant to Cal. Code Civ. Proc. § 2019.210” (“§ 2019.210 Disclosure”). ECF No. 81 at 8; ECF 27 No. 73 at 11, 73-5, Exhibit B. On March 2, 2023, HotSpot filed the instant Motion to Stay 1 Motion to Seal Portions of HotSpot’s Motion to Stay Discovery (ECF No. 72). On March 16, 2 2023, Nurix filed an Opposition to HotSpot’s Motion to Stay Discovery (ECF No. 81), as well as 3 an Administrative Motion to Seal Portions of Nurix’s Opposition (ECF No. 80). On March 23, 4 2023, HotSpot filed a Reply (ECF No. 91), as well as an Administrative Motion to Seal Portions 5 of HotSpot’s Reply (ECF No. 90). On March 27, 2023, Nurix filed Support for the Administrative 6 Motion to Seal Portions of HotSpot’s Reply. ECF No. 92. 7 On March 23, 2023, HotSpot filed a Motion to Strike Portions of Nurix’s Opposition (ECF 8 No. 89), as well as an Administrative Motion to Seal Portions of HotSpot’s Motion to Strike (ECF 9 No. 88). On April 6, 2023, Nurix filed an Opposition to HotSpot’s Motion to Strike (ECF No. 10 97), as well as an Administrative Motion to Seal Nurix’s Opposition (ECF No. 96). On April 13, 11 2023, HotSpot filed a Reply. ECF No. 100. 13 Pending before the Court are the following motions to seal: 14 1. HotSpot’s Motion to Seal Portions of its Motion to Stay Discovery Pending a Complete 15 § 2019.210 Disclosure, ECF No. 72; 16 2. Nurix’s Motion to Seal Portions of its Opposition to HotSpot’s Motion to Stay 17 Discovery, ECF No. 80; 18 3. HotSpot’s Motion to Seal Portions of its Reply, ECF No. 90; 19 4. HotSpot’s Motion to Seal Portions of its Motion to Strike Portions of Nurix’s 20 Opposition, ECF No. 88; and 21 5. Nurix’s Motion to Seal Portions of its Opposition to HotSpot’s Motion to Strike, ECF 22 No. 96. 23 “Historically, courts have recognized a ‘general right to inspect and copy public records 24 and documents, including judicial records and documents.’” Kamakana v. City and Cnty. of 25 Honolulu, 447 F.3d 1172, 1178 (9th Cir. 2006) (quoting Nixon v. Warner Commc’ns, Inc., 435 26 U.S. 589, 597 & n.7 (1978)). Consequently, filings that are “more than tangentially related to the 27 merits of a case” may be sealed only upon a showing of “compelling reasons” for sealing. Ctr. for 1 showing under Rule 26(c) will suffice to keep sealed records attached to non-dispositive motions.” 2 Kamakana v. City & Cnty. of Honolulu, 447 F.3d 1172, 1180 (9th Cir. 2006). See Prolifiq 3 Software Inc. v. Veeva Sys. Inc., No. C 13-03644 SI, 2014 WL 2527148, at *3 (N.D. Cal. June 4, 4 2014) (applying “good cause” standard to joint discovery letter related to § 2019.210 disclosure). 5 Here, the parties seek to seal portions of their motions and briefings that describe the 6 contents of the Agreement, mediation between the parties, and Nurix’s alleged trade secrets. The 7 Court agrees that there is good cause to seal the requested portions relating to the Agreement, 8 confidential mediation communications, and alleged trade secrets. See Regis Metro Associates, 9 Inc. v. NBR Co., LLC, Case No. 20-cv-2309-DMR, 2022 WL 267443, at *14 (N.D. Cal. Jan 28, 10 2022) (granting motion to seal because “[a]ll of the documents contain sensitive business 11 information or may be subject to confidentiality agreements”); Nicolosi Distributing, Inc. v. 12 Finishmaster, Inc., Case No. 18-v-03587-BLF, 2018 WL 10758114, at *2 (N.D. Cal. Aug. 28, 13 2018) (applying compelling reason standard and determining “compelling reasons exist to seal 14 [contracts] because they contain proprietary and confidential business information, including 15 potential trade secrets and business practices, such as product rates and purchase requirements.”); 16 Snapkeys, Ltd. v. Google LLC, No. 19-CV-02658-LHK, 2021 WL 1951250, at *2 (N.D. Cal. May 17 14, 2021) (applying compelling reasons standard and noting “courts have found compelling 18 reasons to seal information regarding a company’s proprietary technology when the disclosure of 19 that information would result in competitive harm.”). The Court has previously sealed the entirety 20 of the Agreement. ECF Nos. 9, 20, 46, 52, 65. See Synchronos Techs., Inc. v. Dropbox Inc., Case 21 No. 16-cv-0119-HSG, 2020 WL 759528, at *5 (N.D. Cal. Feb.

Free access — add to your briefcase to read the full text and ask questions with AI

HotSpot Therapeutics, Inc. v. Nurix Therapeutics, Inc., (N.D. Cal. 2023).

HotSpot Therapeutics, Inc. v. Nurix Therapeutics, Inc. (HotSpot Therapeutics, Inc. v. Nurix Therapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

John Archer v. Mary Deneale
26 U.S. 585 (Supreme Court, 1828)
E. Steven Dutton v. Wolpoff and Abramson
5 F.3d 649 (Third Circuit, 1993)
Diodes, Inc. v. Franzen
260 Cal. App. 2d 244 (California Court of Appeal, 1968)
Advanced Modular Sputtering, Inc. v. Superior Court
33 Cal. Rptr. 3d 901 (California Court of Appeal, 2005)
Perlan Therapeutics, Inc. v. Superior Court
178 Cal. App. 4th 1333 (California Court of Appeal, 2009)
Brescia v. Angelin
172 Cal. App. 4th 133 (California Court of Appeal, 2009)
Altavion, Inc. v. Konica Minolta System Laboratory, Inc.
226 Cal. App. 4th 26 (California Court of Appeal, 2014)
Colpe Investment Co. v. Seeley & Co.
22 P.2d 35 (California Court of Appeal, 1933)
Wimsatt v. Superior Court
152 Cal. App. 4th 137 (California Court of Appeal, 2007)